DATE & TIME
Thursday, January 28
5:15 to 7:30 PM
It's 2010 - What's new/next for the biopharmaceutical industry?
The past few years have witnessed increased consolidation of large Pharma, the gobbling up of biotechs, a spate of licensing activity, the appearance of bio-similars, generic company diversification, and a dwindling capital market. And, all of this before the (possible) passage of health-care reform legislation.
What do these trends portend for our industry? How will they affect your day-to-day functional responsibilities? And, importantly, how do we take advantage of the opportunities and avoid the pitfalls.
On Thursday, January 28, 2010, a distinguished panel of industry experts, listed below, will discuss these and other related matters. They will be prepared to answer your concerns and will raise questions you may not have thought of. It should be interesting, informative, and challenging.
Arnold N. Burstein, Moderator:
Arnold Burstein is a seasoned pharmaceutical executive with over 25 years of experience in marketing, business development, and technical operations. A major portion of his career was spent at Schering-Plough where he held a number of executive positions including Vice President of New Products Marketing, Vice President Manufacturing Development, and Senior Director, Marketing Services.
Mr. Burstein also served as Executive Vice President International Operations and Business Development at Taro Pharmaceuticals. In this capacity he advanced strategic alliances with companies in Germany, Mexico, and Eastern Europe, and established a distribution network in multiple Caribbean, Latin American, and Pacific Rim countries.
Mr. Burstein is currently with the BioLumina Group, a New York City based biopharmaceutical consulting company, focusing on business development, technology assessment, and life cycle management. As Executive Vice President, he is responsible for commercial development and key account management.
Mr. Burstein holds a BA in Economics from Brooklyn College of the City University of New York, and an MBA in Marketing/Management from New York University.
Dennis Purcell currently serves as the Senior Managing Director at Aisling Capital; a leading NY based private equity fund that invests in products, technologies, and global businesses that advance health.
Prior to joining Aisling in 2000, Mr. Purcell was the Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) and served on the Executive Committee of Hambrecht & Quist. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. He was honored in the “Biotech Hall of Fame” by Genetic Engineering News and named to the Biotechnology All-Stars list by Forbes ASAP. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
Mr. Purcell currently serves as a director of Bridge Pharmaceuticals, Inc., Dynova Laboratories, Inc., and Xanodyne Pharmaceuticals, Inc. He is also a member of the Board of Directors of the Biotechnology Industry Organization (BIO) – Emerging Companies Section and has served as a member of the Advisory Council at Harvard Medical School.
Mr. Purcell received his M.B.A. from Harvard University, and his B.S. in Accounting from the University of Delaware.
Richard Sperber is a Business Development Advisor with more than 30 years of U.S. as well as international management and strategy development experience.
Following a decade of domestic marketing management experience, Sperber spent a number of years in Hong Kong as Asia-Pacific Area Director with both Schering-Plough and Wyeth. Later, as a Board Director of Glaxo Ltd. in London, he was responsible for Business Development and Strategic planning.
During the past decade, Mr. Sperber has focused his expertise on facilitating Research, Development and Marketing collaborations in the US, Europe, and Asia.
Mr. Sperber holds a BS/BA degree from the University of Denver and attended the Columbia University Graduate School of Business.
Frankfurt Kurnit Klein & Selz PC
10th Floor Boardroom
488 Madison Avenue (between 51st and 52nd)
New York, NY 10022
View Larger Map
Early, by Jan 22
After Jan 22
Online Registration Deadline: January 27, 12 PM
On-site registration available
No refunds after January 27
Substitutions are welcome